The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
https://doi.org/10.17650/2222-8721-2019-9-2-50-58
Abstract
Dysimmune neuropathies are heterogeneous group of acquired immune-mediated diseases, accompanied by damage to the peripheral nervous system. As a standard therapy, prednisolone and intravenous immunoglobulins are used. Also encouraging efficacy is demonstrated by the use of a genetically engineered chimeric monoclonal antibody to the CD20 antigen found on the surface of normal and malignant B-cells – rituximab. Rituximab shows encouraging results. We reviewed the use of rituximab for dysimmune polyneuropathies and described our experience in administration of Lewis–Sumner syndrome and myelin-associated glycoprotein related neuropathy with rituximab.
About the Authors
V. N. Kiselev
Russian national Center for Emergency and Radiation Medicine n. a. A. M. Nikiforova
Russian Federation
54 Optikov St., Saint-Peterburg 197374, Russia
Russian Federation
54 Optikov St., Saint-Peterburg 197374, Russia
V. G. Potapenko
City Clinical Hospital № 31
Russian Federation
3 Dinamo Prospect, Saint-Peterburg 197110, Russia
Russian Federation
3 Dinamo Prospect, Saint-Peterburg 197110, Russia
References
1. Mathey E.K., Park S.B., Hughes R.A.C. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015;86(9):973–85. DOI: 10.1136/jnnp-2014-309697. PMID: 25677463.
2. Suponevа N.А., Naumovа E.S., Gnedovskaya E.V. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Nervnomyshechnye bolezni = Neuromuscular Diseases. 2016;6(1):44-53. (In Russ.).DOI: 10.17650/2222-8721-2016-6-1-44-53.
3. Gazzola S., Delmont E., Franques J. et al. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci 2017;377:144–8. DOI: 10.1016/j.jns.2017.04.015. PMID: 28477685.
4. Yakovlev A.A., Gapeshin R.A., Smochilin A.G., Yakovleva M.V. Evaluation of human immunoglobulin effectiveness in patients with sensory-motor polyneuropathy associated with monoclonal gammapathy of undetermined significance. Arkhiv vnutrenney mediciny = The Russian Archives of Internal Medicine 2018;8(4):278–84. (In Russ.). DOI: 10.20514/2226-6704-2018-8-4-278-284.
5. Ginzberg M.A., Varlamova E.Yu., Ryzhko V.V. et al. Clinical and neurophysiological study of chronic demyelinating polyneuropathy associated with monoclonal secretion. Medicinskiy sovet = Medical Council 2015;10:93–6. (In Russ.).
6. Suponeva N.A., Nikitin S.S., Varlamova E.Yu. et al. Monoclonal gammopathy in the structure of chronic sensorimotor polyneuropathy of unknown origin: laboratory diagnostics. Vrach = Physician 2010;11:70–2. (In Russ.).
7. Muley S.A., Parry G.J. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol 2009;11:221–7. DOI: 10.1007/s11940-009-0026-4. PMID: 19364457.
8. Knecht H., Baumberger M., Tobòn A., Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004;63(4):730–2. DOI: 10.1212/01.WNL.0000134606.50529.C7. PMID: 15326255.
9. Bodley-Scott D.D. Chronic inflammatory demyelinating polyradiculoneuropathy responding to rituximab. Pract Neurol 2005;5:242–5. DOI: 10.1111/j.1474-7766.2005.00328.x.
10. Gorson K.C., Natarajan N., Ropper A.H. et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve 2007:35(1):66–9. DOI: 10.1002/mus.20664. PMID: 16967492.
11. Münch C., Anagnostou P., Meyer R., Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 2007;256(1–2):100–2. DOI: 10.1016/j.jns.2007.02.027. PMID: 17382963.
12. Sadnicka A., Reilly M.M., Mummery C. et al. Rituximab in the treatment of three coexistent neurological autoimmune diseases: Chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82(2):230–2. DOI: 10.1136/jnnp.2009.174888. PMID: 20462915.
13. Benedetti L., Briani C., Franciotta D. et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011;82(3):306–8. DOI: 10.1136/jnnp.2009.188912. PMID: 20639381.
14. Querol L., Rojas-García R., Diaz-Manera J. et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015;2(5):e149. DOI: 10.1212/NXI.0000000000000149. PMID: 26401517.
15. Renaud S., Gregor M., Fuhr P. et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27(5):611–5. DOI 10.1002/mus.10359. PMID: 12707982.
16. Broglio L., Lauria G. Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve 2005;32(3):378–9. DOI: 10.1002/mus.20386. PMID: 15986418.
17. Renaud S., Fuhr P., Gregor M. et al. High-dose rituximab and anti-MAG–associated polyneuropathy. Neurology 2006;66(5):742–4. DOI: 10.1212/01.wnl.0000201193.00382.b3. PMID: 16534115.
18. Benedetti L., Briani C, Grandis M. et al. Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;12:102–7. DOI: 10.1111/j.1529-8027.2007.00129. x. PMID: 17565535.
19. Zara G., Zambello R., Ermani M. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. Clin Neurophysiol 2011;122(12):2518–22. DOI: 10.1016/j.clinph.2011.05.015. PMID: 21680240.
20. Dalakas M.C., Rakocevic G., Salajegheh M. et al. Placebo-controlled trial of rituximab in IgM anti-myelinassociated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65(3):286–93. DOI: 10.1002/ana.21577. PMID: 19334068.
21. Léger J.M., Viala K., Nicolas G. et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 2013;80(24):2217–25. DOI: 10.1212/WNL.0b013e318296e92b. PMID: 23667063.
22. Campagnolo M., Zambello R., Nobile-Orazio E. et al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. J Neurol Neurosurg Psychiatry 2017;88:1094–7. DOI: 10.1136/jnnp-2017-315736. PMID: 28501820.
23. Attarian S.,Verschueren A., Franques J. et al. Response to treatment in patients with Lewis-Sumner syndrome. Muscle Nerve 2011;44(2):179–84. DOI: 10.1002/mus.22024.
Review
For citations:
Kiselev V.N., Potapenko V.G. The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review. Neuromuscular Diseases. 2019;9(2):50-58. (In Russ.) https://doi.org/10.17650/2222-8721-2019-9-2-50-58
Views:
1637
Email this article 